| Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis DY Wang, JE Salem, JV Cohen, S Chandra, C Menzer, F Ye, S Zhao, ... JAMA oncology 4 (12), 1721-1728, 2018 | 1944 | 2018 |
| Myocarditis in patients treated with immune checkpoint inhibitors SS Mahmood, MG Fradley, JV Cohen, A Nohria, KL Reynolds, ... Journal of the American College of Cardiology 71 (16), 1755-1764, 2018 | 1210 | 2018 |
| Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial SB Goldberg, SN Gettinger, A Mahajan, AC Chiang, RS Herbst, M Sznol, ... The lancet oncology 17 (7), 976-983, 2016 | 1015 | 2016 |
| CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer EM Bange, NA Han, P Wileyto, JY Kim, S Gouma, J Robinson, ... Nature medicine 27 (7), 1280-1289, 2021 | 420 | 2021 |
| High‐dose glucocorticoids for the treatment of ipilimumab‐induced hypophysitis is associated with reduced survival in patients with melanoma AT Faje, D Lawrence, K Flaherty, C Freedman, R Fadden, K Rubin, ... Cancer 124 (18), 3706-3714, 2018 | 394 | 2018 |
| Cutaneous T-cell lymphoma: malignant proliferation of T-regulatory cells CL Berger, R Tigelaar, J Cohen, K Mariwalla, J Trinh, N Wang, ... Blood 105 (4), 1640-1647, 2005 | 321 | 2005 |
| Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis L Zhang, M Awadalla, SS Mahmood, A Nohria, MZO Hassan, F Thuny, ... European heart journal 41 (18), 1733-1743, 2020 | 255 | 2020 |
| Long-term survival of patients with melanoma with active brain metastases treated with pembrolizumab on a phase II trial HM Kluger, V Chiang, A Mahajan, CR Zito, M Sznol, T Tran, SA Weiss, ... Journal of Clinical Oncology 37 (1), 52-60, 2019 | 246 | 2019 |
| Global longitudinal strain and cardiac events in patients with immune checkpoint inhibitor-related myocarditis M Awadalla, SS Mahmood, JD Groarke, MZO Hassan, A Nohria, A Rokicki, ... Journal of the American College of Cardiology 75 (5), 467-478, 2020 | 209 | 2020 |
| Major adverse cardiovascular events and the timing and dose of corticosteroids in immune checkpoint Inhibitor–Associated myocarditis L Zhang, DA Zlotoff, M Awadalla, SS Mahmood, A Nohria, MZO Hassan, ... Circulation 141 (24), 2031-2034, 2020 | 162 | 2020 |
| Severe neurological toxicity of immune checkpoint inhibitors: growing spectrum D Dubey, WS David, KL Reynolds, DF Chute, NF Clement, JV Cohen, ... Annals of neurology 87 (5), 659-669, 2020 | 154 | 2020 |
| Immune checkpoint inhibitor therapy in patients with preexisting inflammatory bowel disease H Abu-Sbeih, DM Faleck, B Ricciuti, RB Mendelsohn, AR Naqash, ... Journal of Clinical Oncology 38 (6), 576, 2020 | 154 | 2020 |
| A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis DB Johnson, WJ McDonnell, PI Gonzalez-Ericsson, RN Al-Rohil, ... Nature medicine 25 (8), 1243-1250, 2019 | 152 | 2019 |
| PD-L1 studies across tumor types, its differential expression and predictive value in patients treated with immune checkpoint inhibitors HM Kluger, CR Zito, G Turcu, MK Baine, H Zhang, A Adeniran, M Sznol, ... Clinical Cancer Research 23 (15), 4270-4279, 2017 | 151 | 2017 |
| Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis A Faje, K Reynolds, L Zubiri, D Lawrence, JV Cohen, RJ Sullivan, ... European journal of endocrinology 181 (3), 211-219, 2019 | 133 | 2019 |
| Melanoma brain metastasis pseudoprogression after pembrolizumab treatment JV Cohen, AK Alomari, AO Vortmeyer, LB Jilaveanu, SB Goldberg, ... Cancer immunology research 4 (3), 179-182, 2016 | 131 | 2016 |
| Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies D Dubey, WS David, AA Amato, KL Reynolds, NF Clement, DF Chute, ... Neurology 93 (11), e1093-e1103, 2019 | 130 | 2019 |
| Melanoma central nervous system metastases: current approaches, challenges, and opportunities JV Cohen, H Tawbi, KA Margolin, R Amravadi, M Bosenberg, ... Pigment cell & melanoma research 29 (6), 627-642, 2016 | 123 | 2016 |
| Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection M Tio, R Rai, OM Ezeoke, JL McQuade, L Zimmer, C Khoo, JJ Park, ... European Journal of Cancer 104, 137-144, 2018 | 115 | 2018 |
| Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors AC Guidon, LB Burton, BK Chwalisz, J Hillis, TH Schaller, AA Amato, ... Journal for immunotherapy of cancer 9 (7), 2021 | 113 | 2021 |
